Compare Novartis AG (NVS) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Verisign, Inc. — how do they compare? Novartis AG trades at $143.2 (market cap $268.57B), while Verisign, Inc. trades at $304.11 (market cap $26.92B). The key difference: Novartis AG is far larger — about 10× Verisign, Inc.'s market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Verisign, Inc. for 123 Days on average.
| NVS | VRSN | |
|---|---|---|
Market Cap | $268.57B | $26.92B |
Volume | 1,532,573 | 1,921,402 |
Sector | Health | Technology |
52-Week High | $168.62 | $310.00 |
52-Week Low | $121.80 | $211.49 |
Typical Hold Time | 82 Days | 123 Days |
Enterprise Value | $309.89B | $28.23B |
Dividend Yield | 3.31% | 1.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
VeriSign (VRSN) trades at $301.59, up 2.5% today, with a bullish technical signal and strong institutional buying. The company reported robust Q2 2026 earnings with revenue up 6% year-over-year and EPS of $2.38, though it missed expectations. High profitability is evident with a net income margin near 50%, and cash flow trends are improving. Recent news includes a class-action antitrust lawsuit and insider selling by the CEO, but analyst consensus remains positive.
The outlook is supported by solid fundamentals and a consensus price target of $348, offering ~15% upside. Key risks include legal challenges from the antitrust suit and reliance on domain registration growth. Earnings momentum and institutional accumulation provide tailwinds, but investors should weigh litigation risks against the company's stable cash flows and market position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
